The safety of Covid-19 mRNA vaccines: a review | Patient Safety in Surgery

  • 1.

    Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID–19): a review. JAMA. 2020;324(8):782–93.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 2.

    Vabret N. Preclinical data from SARS-CoV–2 mRNA vaccine. Nat Rev Immunol. 2020;20(8):461.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 3.

    Ahammad I, Lira SS. Designing a novel mRNA vaccine against SARS-CoV–2: An immunoinformatics approach. Int J Biol Macromol. 2020;162:820–37.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 4.

    Rahman IU, Ali N, Ijaz F, Afzal A, Abd Allah EF. COVID–19 – Important considerations for developing and using a vaccine. Hum Vaccin Immunother. 2020:1–2.

  • 5.

    Lombard M, Pastoret PP, Moulin AM. A brief history of vaccines and vaccination. Rev Sci Tech. 2007;26(1):29–48.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 6.

    Plotkin SA. Vaccines: past, present and future. Nat Med. 2005;11(4 Suppl):S5-11.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 7.

    Plotkin SA. Vaccines: the fourth century. Clin Vaccine Immunol. 2009;16(12):1709–19.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 8.

    Hajj Hussein I, Chams N, Chams S, El Sayegh S, Badran R, Raad M, Gerges-Geagea A, Leone A, Jurjus A. Vaccines through centuries: major cornerstones of global health. Front Public Health. 2015;3:269.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 9.

    Biggs PM. Gordon memorial lecture. Vaccines and vaccination – past, present and future. Br Poult Sci. 1990;31(1):3–22.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 10.

    Davenport FM. Inactivated influenza virus vaccines. Past, present, and future. Am Rev Respir Dis. 1961;832(2)Pt):146–56.

    Google Scholar 

  • 11.

    Plotkin SA, Rees J. Vaccines: facing complex problems with the promise of immunology. Expert Rev Vaccines. 2014;13(8):939–41.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 12.

    Blakney AK, Ip S, Geall AJ. An update on self-amplifying mRNA vaccine development. Vaccines (Basel). 2021;9(2):97.

    Article 

    Google Scholar 

  • 13.

    Plotkin SA. Updates on immunologic correlates of vaccine-induced protection. Vaccine. 2020;38(9):2250–7.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 14.

    Pascolo S. Synthetic messenger RNA-based vaccines: from scorn to hype. Viruses. 2021;13(2):270.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 15.

    Piret J, Boivin G. Pandemics throughout history. Front Microbiol. 2020;11:631736.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 16.

    Ho W, Gao M, Li F, Li Z, Zhang XQ, Xu X: Next-generation vaccines: nanoparticle-mediated DNA and mRNA delivery. Adv Healthc Mater 2021:e2001812.

  • 17.

    Xu S, Yang K, Li R, Zhang L. mRNA vaccine era-mechanisms, drug platform and clinical prospection. Int J Mol Sci. 2020;21(18):6582.

    CAS 
    Article 

    Google Scholar 

  • 18.

    Van Lint S, Heirman C, Thielemans K, Breckpot K. mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic. Hum Vaccin Immunother. 2013;9(2):265–74.

    PubMed 
    PubMed Central 
    Article 
    CAS 

    Google Scholar 

  • 19.

    Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ. Developing mRNA-vaccine technologies. RNA Biol. 2012;9(11):1319–30.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 20.

    Gergen J, Petsch B: mRNA-based vaccines and mode of action. Curr Top Microbiol Immunol 2021 [Feb 17, online ahead of print].

  • 21.

    Lu J, Lu G, Tan S, Xia J, Xiong H, Yu X, Qi Q, Yu X, Li L, Yu H, et al. A COVID–19 mRNA vaccine encoding SARS-CoV–2 virus-like particles induces a strong antiviral-like immune response in mice. Cell Res. 2020;30(10):936–9.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 22.

    Meyer M, Huang E, Yuzhakov O, Ramanathan P, Ciaramella G, Bukreyev A. Modified mRNA-based vaccines elicit robust immune responses and protect guinea pigs from Ebola virus disease. J Infect Dis. 2018;217(3):451–5.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 23.

    Rauch S, Jasny E, Schmidt KE, Petsch B: Newvaccinetechnologiestocombatoutbreaksituations. FrontImmunol 2018,9:1963.

  • 24.

    Linares-Fernandez S, Lacroix C, Exposito JY, Verrier B. Tailoring mRNA vaccine to balance innate/adaptive immune response. Trends Mol Med. 2020;26(3):311–23.

    CAS 
    Article 

    Google Scholar 

  • 25.

    Sandbrink JB, Shattock RJ. RNA vaccines: a suitable platform for tackling emerging pandemics? Front Immunol. 2020;11:608460.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 26.

    Zhang NN, Li XF, Deng YQ, Zhao H, Huang YJ, Yang G, Huang WJ, Gao P, Zhou C, Zhang RR, et al. A thermostable mRNA vaccine against COVID–19. Cell. 2020;182(5):1271-1283 e1216.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 27.

    Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009;8(2):129–38.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 28.

    Reichmuth AM, Oberli MA, Jaklenec A, Langer R, Blankschtein D. mRNA vaccine delivery using lipid nanoparticles. Ther Deliv. 2016;7(5):319–34.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 29.

    Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Perez Marc G, Moreira ED, Zerbini C, et al. Safety and Efficacy of the BNT162b2 mRNA Covid–19 Vaccine. N Engl J Med. 2020;383(27):2603–15.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 30.

    Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, et al. Efficacy and Safety of the mRNA–1273 SARS-CoV–2 Vaccine. N Engl J Med. 2021;384(5):403–16.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 31.

    Castells MC, Phillips EJ. Maintaining safety with SARS-CoV–2 vaccines. N Engl J Med. 2021;384(7):643–9.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 32.

    Caminati M, Guarnieri G, Senna G. Who is really at risk for anaphylaxis due to COVID–19 vaccine? Vaccines (Basel). 2021;9(1):38.

    Article 

    Google Scholar 

  • 33.

    Turner PJ, Ansotegui IJ, Campbell DE, Cardona V, Ebisawa M, El-Gamal Y, Fineman S, Geller M, Gonzalez-Estrada A, Greenberger PA, et al. COVID–19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee. World Allergy Organ J. 2021;14(2):100517.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 34.

    Cirillo N. Reported orofacial adverse effects of COVID–19 vaccines: The knowns and the unknowns. J Oral Pathol Med. 2021 [Feb 1, online ahead of print].

  • 35.

    Repajic M, Lai XL, Xu P, Liu A. Bell’s Palsy after second dose of Pfizer COVID–19 vaccination in a patient with history of recurrent Bell’s palsy. Brain Behav Immun Health. 2021;13:100217.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 36.

    Connors J, Bell MR, Marcy J, Kutzler M, Haddad EK. The impact of immunoaging on SARS- CoV–2 vaccine development. Geroscience. 2021. Online ahead of print.

  • 37.

    Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, et al. Safety and immunogenicity of SARS-CoV–2 mRNA–1273 vaccine in older adults. N Engl J Med. 2020;383(25):2427–38.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 38.

    Delahoy MJ, Whitaker M, O’Halloran A, Chai SJ, Kirley PD, Alden N, Kawasaki B, Meek J, Yousey-Hindes K, Anderson EJ, et al. Characteristics and Maternal and Birth Outcomes of Hospitalized Pregnant Women with Laboratory-Confirmed COVID–19 – COVID-NET, 13 States, March 1-August 22, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(38):1347–54.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 39.

    Woodworth KR, Olsen EO, Neelam V, Lewis EL, Galang RR, Oduyebo T, Aveni K, Yazdy MM, Harvey E, Longcore ND, et al. Birth and infant outcomes following laboratory-confirmed SARS-CoV–2 infection in pregnancy – SET-NET, 16 Jurisdictions, March 29-October 14, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(44):1635–40.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 40.

    Vermillion MS, Klein SL. Pregnancy and infection: using disease pathogenesis to inform vaccine strategy. NPJ Vaccines. 2018;3:6.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 41.

    Klein SL, Creisher PS, Burd I. COVID–19 vaccine testing in pregnant females is necessary. J Clin Invest. 2021;131(5):e147553.

    CAS 
    Article 

    Google Scholar 

  • 42.

    Walsh EE, Frenck RW, Falsey AR Jr., Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R. Safety and immunogenicity of bwo RNA-based Covid–19 vaccine candidates. N Engl J Med. 2020;383(25):2439–50.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 43.

    Saito S, Nakashima A, Shima T, Ito M. Th1/Th2/Th17 and regulatory T-cell paradigm in pregnancy. Am J Reprod Immunol. 2010;63(6):601–10.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 44.

    Helmo FR, Alves EAR, Moreira RAA, Severino VO, Rocha LP, Monteiro M, Reis MAD, Etchebehere RM, Machado JR, Correa RRM. Intrauterine infection, immune system and premature birth. J Matern Fetal Neonatal Med. 2018;31(9):1227–33.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 45.

    Adhikari EH, Moreno W, Zofkie AC, MacDonald L, McIntire DD, Collins RRJ, Spong CY. Pregnancy outcomes among women with and without severe acute respiratory syndrome coronavirus 2 infection. JAMA Netw Open. 2020;3(11):e2029256.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 46.

    Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, Baum A, Pascal K, Quandt J, Maurus D, et al. COVID–19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020;586(7830):594–9.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 47.

    Sonani B, Aslam F, Goyal A, Patel J, Bansal P. COVID–19 vaccination in immunocompromised patients. Clin Rheumatol. 2021;40(2):797–8.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 48.

    Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, et al. An mRNA vaccine against SARS-CoV–2 – preliminary report. N Engl J Med. 2020;383(20):1920–31.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 49.

    Cordero DA: Rebuilding public trust: a clarified response to COVID–19 vaccine hesitancy predicament. J Public Health (Oxf) 2021. [Feb 5, online ahead of print].

  • 50.

    Dror AA, Eisenbach N, Taiber S, Morozov NG, Mizrachi M, Zigron A, Srouji S, Sela E. Vaccine hesitancy: the next challenge in the fight against COVID–19. Eur J Epidemiol. 2020;35(8):775–9.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 51.

    Lurie N, Saville M, Hatchett R, Halton J. Developing Covid–19 vaccines at pandemic speed. N Engl J Med. 2020;382(21):1969–73.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 52.

    Kreps S, Prasad S, Brownstein JS, Hswen Y, Garibaldi BT, Zhang B, Kriner DL. Factors associated with US adults’ likelihood of accepting COVID–19 vaccination. JAMA Netw Open. 2020;3(10):e2025594.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 53.

    Malik AA, McFadden SM, Elharake J, Omer SB. Determinants of COVID–19 vaccine acceptance in the US. EClinicalMedicine. 2020;26:100495.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 54.

    Reiter PL, Pennell ML, Katz ML. Acceptability of a COVID–19 vaccine among adults in the United States: How many people would get vaccinated? Vaccine. 2020;38(42):6500–7.

    PubMed 
    PubMed Central 
    Article 
    CAS 

    Google Scholar 

  • 55.

    Hardt K, Bonanni P, King S, Santos JI, El-Hodhod M, Zimet GD, Preiss S. Vaccine strategies: optimising outcomes. Vaccine. 2016;34(52):6691–9.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 56.

    Brewer NT, Hall ME, Malo TL, Gilkey MB, Quinn B, Lathren C. Announcements versus conversations to improve HPV vaccinationa coverage: a randomized trial. Pediatrics. 2017;139(1):e20161764.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 57.

    Jacobson RM, Agunwamba AA, St Sauver JL, Finney Rutten LJ. The most effective and promising population health strategies to advance human papillomavirus vaccination. Expert Rev Vaccines. 2016;15(2):257–69.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 58.

    Schaffer DeRoo S, Pudalov NJ, Fu LY. Planning for a COVID–19 vaccination program. JAMA. 2020;323(24):2458–9.

    PubMed 
    PubMed Central 
    Article 
    CAS 

    Google Scholar 

  • 59.

    Chou WS, Budenz A. Considering emotion in COVID–19 vaccine communication: addressing vaccine hesitancy and fostering vaccine confidence. Health Commun. 2020;35(14):1718–22.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar 

  • 60.

    Kaiser Family Foundation: COVID–19 Vaccine Monitor: December2020.https://www.kff.org/coronavirus-covid-19/report/kff-covid-19-vaccine-monitor-december-2020/. Accessed 5 Apr 2021.

  • Related Articles

    Leave a Reply

    Back to top button